Rexahn Pharmaceuticals, Inc. (RNN) Initiates Phase 1b Clinical Trial Of RX-3117 For Treatment Of Solid Tumors
1/8/2014 10:06:04 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by